Latent cytokines for targeted therapy of inflammatory disorders

Expert Opinion on Drug Delivery

Volumn 11, Issue 1, 2014, Pages 101-110

  Mullen, Lisa ^a   Adams, Gill ^a   Layward, Lorna ^a   Vessillier, Sandrine ^a   Annenkov, Alex ^a   Mittal, Gayatri ^a   Rigby, Anne ^a   Sclanders, Michelle ^a   Baker, David ^a   Gould, David ^a   Chernajovsky, Yuti ^a,b  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b Stealthyx Therapeutics Ltd   (United Kingdom)

Author keywords

Immunocytokines; Inflammation; Latency associated peptide; Latent cytokines

Indexed keywords

CYTOKINE; HYBRID PROTEIN; LATENCY ASSOCIATED PEPTIDE; LIPOSOME; MATRIX METALLOPROTEINASE; TRANSFORMING GROWTH FACTOR BETA; LATENCY-ASSOCIATED PROPEPTIDE, TGF-BETA; PEPTIDE; PROTEIN PRECURSOR;

AUTOINFLAMMATORY DISEASE; ENCAPSULATION; HUMAN; IMMUNOGENICITY; LATENT PERIOD; NONHUMAN; PROTEIN CLEAVAGE; PROTEIN TARGETING; REVIEW; ANIMAL; CHEMISTRY; DRUG DELIVERY SYSTEM; INFLAMMATION;

ANIMALS; CYTOKINES; DRUG DELIVERY SYSTEMS; HUMANS; INFLAMMATION; PEPTIDES; PROTEIN PRECURSORS; TRANSFORMING GROWTH FACTOR BETA;

EID: 84890775703     PISSN: 17425247     EISSN: 17447593     Source Type: Journal    
DOI: 10.1517/17425247.2014.863872     Document Type: Review

References (87)

1. Oppenheim JJ. Cytokines: Past, present, and future. Int J Hematol 2001;74:3-8
2. Francis GE, Fisher D, Delgado C, et al. PEGylation of cytokines and other therapeutic proteins and peptides: The importance of biological optimisation of coupling techniques. Int J Hematol 1998;68:1-18
3. DeFrees S, Wang ZG, Xing R, et al. GlycoPEGylation of recombinant therapeutic proteins produced in Escherichia coli. Glycobiology 2006;16:833-43
4. Veronese FM, Mero A. The impact of PEGylation on biological therapies. BioDrugs 2008;22:315-29
5. Ceaglio N, Etcheverrigaray M, Kratje R, et al. Influence of carbohydrates on the stability and structure of a hyperglycosylated human interferon alpha mutein. Biochimie 2010;92:971-8
6. Subramanian G, Fiscella M, Lamouse-Smith A, et al. Albinterferon alpha-2b: A genetic fusion protein for the treatment of chronic hepatitis C. Nat Biotechnol 2007;25:1411-19
7. Rycroft D, Holt LJ. Methods for determining the PK parameters of AlbudAbs and of long serum half-life drugs made using the AlbudAb technology. Methods Mol Biol 2012;911:457-73
8. Kedar E, Palgi O, Golod G, et al. Delivery of cytokines by liposomes. III. Liposome-encapsulated GM-CSF and TNF-Alpha show improved pharmacokinetics and biological activity and reduced toxicity in mice. J Immunother 1997;20:180-93
9. Abuchowski A, McCoy JR, Palczuk NC, et al. Effect of covalent attachment of polyethylene glycol on immunogenicity and circulating life of bovine liver catalase. J Biol Chem 1977;252:3582-6
10. Abuchowski A, van Es T, Palczuk NC, et al. Alteration of immunological properties of bovine serum albumin by covalent attachment of polyethylene glycol. J Biol Chem 1977;252:3578-81
11. Pasut G, Veronese FM. PEGylation for improving the effectiveness of therapeutic biomolecules. Drugs Today (Barc) 2009;45:687-95
12. Kinstler OB, Brems DN, Lauren SL, et al. Characterization and stability of Nterminally PEGylated rhG-CSF. Pharm Res 1996;13:996-1002
13. Bailon P, Palleroni A, Schaffer CA, et al. Rational design of a potent, long-lasting form of interferon: A 40 kDa branched polyethylene glycol-conjugated interferon alpha-2a for the treatment of hepatitis C. Bioconjug Chem 2001;12:195-202
14. Wang YS, Youngster S, Grace M, et al. Structural and biological characterization of pegylated recombinant interferon alpha-2b and its therapeutic implications. Adv Drug Deliv Rev 2002;54:547-70
15. Elliott S, Lorenzini T, Asher S, et al. Enhancement of therapeutic protein in vivo activities through glycoengineering. Nat Biotechnol 2003;21:414-21
16. Higuchi M, Oh-eda M, Kuboniwa H, et al. Role of sugar chains in the expression of the biological activity of human erythropoietin. J Biol Chem 1992;267:7703-9
17. Egrie JC, Browne JK. Development and characterization of novel erythropoiesis stimulating protein (NESP). Br J Cancer 2001;84(1):3-10
18. Nissenson AR. Novel erythropoiesis stimulating protein for managing the anemia of chronic kidney disease. Am J Kidney Dis 2001;38(6):1390-7
19. Halpern W, Riccobene TA, Agostini H, et al. Albugranin, a recombinant human granulocyte colony stimulating factor (GCSF) genetically fused to recombinant human albumin induces prolonged myelopoietic effects in mice and monkeys. Pharm Res 2002;19:1720-9
20. Cordes AA, Carpenter JF, Randolph TW. Selective domain stabilization as a strategy to reduce human serum albumin-human granulocyte colony stimulating factor aggregation rate. J Pharm Sci 2012;101:2009-16
21. Yao Z, Dai W, Perry J, et al. Effect of albumin fusion on the biodistribution of interleukin-2. Cancer Immunol Immunother 2004;53:404-10
22. Joung CH, Shin JY, Koo JK, et al. Production and characterization of longacting recombinant human albumin-EPO fusion protein expressed in CHO cell. Protein Expr Purif 2009;68:137-45
23. Zhao HL, Xue C, Wang Y, et al. Circumventing the heterogeneity and instability of human serum albumin-interferon-Alpha2b fusion protein by altering its orientation. J Biotechnol 2007;131:245-52
24. Zhao HL, Xue C, Wang Y, et al. Elimination of the free sulfhydryl group in the human serum albumin (HSA) moiety of human interferon-Alpha2b and HSA fusion protein increases its stability against mechanical and thermal stresses. Eur J Pharm Biopharm 2009;72:405-11
25. Holt LJ, Basran A, Jones K, et al. Anti-serum albumin domain antibodies for extending the half-lives of short lived drugs. Protein Eng Des Sel 2008;21:283-8
26. Walker A, Dunlevy G, Rycroft D, et al. Anti-serum albumin domain antibodies in the development of highly potent, efficacious and long-Acting interferon. Protein Eng Des Sel 2010;23:271-8
27. Storm G, Crommelin D. Liposomes: Quo vadis? Pharm Sci Technol Today 1998;1:19-31
28. Kedar E, Rutkowski Y, Braun E, et al. Delivery of cytokines by liposomes. I. Preparation and characterization of interleukin-2 encapsulated in longcirculating sterically stabilized liposomes. J Immunother Emphasis Tumor Immunol 1994;16:47-59
29. Kedar E, Braun E, Rutkowski Y, et al. Delivery of cytokines by liposomes. II. Interleukin-2 encapsulated in longcirculating sterically stabilized liposomes: Immunomodulatory and anti-Tumor activity in mice. J Immunother Emphasis Tumor Immunol 1994;16:115-24
30. Kedar E, Gur H, Babai I, et al. Delivery of cytokines by liposomes: Hematopoietic and immunomodulatory activity of interleukin-2 encapsulated in conventional liposomes and in longcirculating liposomes. J Immunother 2000;23:131-45
31. Rachmawati H, Reker-Smit C, Lub-de Hooge MN, et al. Chemical modification of interleukin-10 with mannose 6-phosphate groups yields a liver-selective cytokine. Drug Metab Dispos 2007;35:814-21
32. Bansal R, Prakash J, de Ruijter M, et al. Peptide-modified albumin carrier explored as a novel strategy for a cellspecific delivery of interferon gamma to treat liver fibrosis. Mol Pharm 2011;8:1899-909
33. Bansal R, Prakash J, Post E, et al. Novel engineered targeted interferon-gamma blocks hepatic fibrogenesis in mice. Hepatology 2011;54:586-96
34. Bansal R, Tomar T, Ostman A, et al. Selective targeting of interferon gamma to stromal fibroblasts and pericytes as a novel therapeutic approach to inhibit angiogenesis and tumor growth. Mol Cancer Ther 2012;11:2419-28
35. Pinzani M, Milani S, Herbst H, et al. Expression of platelet-derived growth factor and its receptors in normal human liver and during active hepatic fibrogenesis. Am J Pathol 1996;148:785-800
36. Pasqualini R, Koivunen E, Kain R, et al. Aminopeptidase N is a receptor for tumor-homing peptides and a target for inhibiting angiogenesis. Cancer Res 2000;60:722-7
37. Di Matteo P, Arrigoni GL, Alberici L, et al. Enhanced expression of CD13 in vessels of inflammatory and neoplastic tissues. J Histochem Cytochem 2011;59:47-59
38. Arap W, Pasqualini R, Ruoslahti E. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science 1998;279:377-80
39. Curnis F, Sacchi A, Borgna L, et al. Enhancement of tumor necrosis factor alpha antitumor immunotherapeutic properties by targeted delivery to aminopeptidase N (CD13). Nat Biotechnol 2000;18:1185-90
40. Corti A, Curnis F, Rossoni G, et al. Peptide-mediated targeting of cytokines to tumor vasculature: The NGR-hTNF example. BioDrugs 2013; Epub ahead of print
41. Gutbrodt KL, Neri D. Immunocytokines. Antibodies 2012;1:70-87
42. Savage P, So A, Spooner RA, et al. A recombinant single-chain antibody interleukin-2 fusion protein. Cell Biophys 1993;22:61-77
43. Reisfeld RA, Becker JC, Gillies SD. Immunocytokines: A new approach to immunotherapy of melanoma. Melanoma Res 1997;7:S99-106
44. Dela Cruz JS, Trinh KR, Morrison SL, et al. Recombinant anti-human HER2/ neu IgG3-(GM-CSF) fusion protein retains antigen specificity and cytokine function and demonstrates antitumor activity. J Immunol 2000;165:5112-21
45. Fyfe G, Fisher RI, Rosenberg SA, et al. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol 1995;13:688-96
46. Eggermont AM, Schraffordt Koops H, Lienard D, et al. Isolated limb perfusion with high-dose tumor necrosis factoralpha in combination with interferongamma and melphalan for nonresectable extremity soft tissue sarcomas: A multicenter trial. J Clin Oncol 1996;14:2653-65
47. Pini A, Viti F, Santucci A, et al. Design and use of a phage display library. Human antibodies with subnanomolar affinity against a marker of angiogenesis eluted from a two-dimensional gel. J Biol Chem 1998;73:21769-76
48. Borsi L, Balza E, Bestagno M, et al. Selective targeting of tumoral vasculature: Comparison of different formats of an antibody (L19) to the ED-B domain of fibronectin. Int J Cancer 2002;102:75-85 [37].
49. Muro AF, Caputi M, Pariyarath R, et al. Regulation of fibronectin EDA exon alternative splicing: Possible role of RNA secondary structure for enhancer display. Mol Cell Biol 1999;19:2657-71
50. Zardi L, Carnemolla B, Siri A, et al. Transformed human cells produce a new fibronectin isoform by preferential alternative splicing of a previously unobserved exon. EMBO J 1987;6:2337-42
51. Castellani P, Viale G, Dorcaratto A, et al. The fibronectin isoform containing the ED-B oncofetal domain: A marker of angiogenesis. Int J Cancer 1994;59:612-18
52. Rybak JN, Trachsel E, Scheuermann J, et al. Ligand-based vascular targeting of disease. ChemMedChem 2007;2:22-40
53. Villa A, Trachsel E, Kaspar M, et al. A high-Affinity human monoclonal antibody specific to the alternatively spliced EDA domain of fibronectin efficiently targets tumor neo-vasculature in vivo. Int J Cancer 2008;122:2405-13
54. Sommavilla R, Pasche N, Trachsel E, et al. Expression, engineering and characterization of the tumor-Targeting heterodimeric immunocytokine F8-IL12. Protein Eng Des Sel 2010;23:653-61
55. Pasche N, Frey K, Neri D. The targeted delivery of IL17 to the mouse tumor neo-vasculature enhances angiogenesis but does not reduce tumor growth rate. Angiogenesis 2012;15:165-9
56. Pasche N, Wulhfard S, Pretto F, et al. The antibody-based delivery of interleukin-12 to the tumor neovasculature eradicates murine models of cancer in combination with paclitaxel. Clin Cancer Res 2012;18:4092-103
57. Pasche N, Woytschak J, Wulhfard S, et al. Cloning and characterization of novel tumor-Targeting immunocytokines based on murine IL7. J Biotechnol 2011;154:84-92
58. Trachsel E, Bootz F, Silacci M, et al. Antibody-mediated delivery of IL-10 inhibits the progression of established collagen-induced arthritis. Arthritis Res Ther 2007;9:R9
59. Schwager K, Kaspar M, Bootz F, et al. Preclinical characterization of DEKAVIL (F8-IL10), a novel clinical-stage immunocytokine which inhibits the progression of collagen-induced arthritis. Arthritis Res Ther 2009;11:R142
60. Hughes C, Faurholm B, Dell'Accio F, et al. Human single-chain variable fragment that specifically targets arthritic cartilage. Arthritis Rheum 2010;62:1007-16
61. Nissim A, Winyard PG, Corrigall V, et al. Generation of neoantigenic epitopes after posttranslational modification of type II collagen by factors present within the inflamed joint. Arthritis Rheum 2005;52:3829-38
62. Wythe SE, DiCara D, Taher TE, et al. Targeted delivery of cytokine therapy to rheumatoid tissue by a synovial targeting peptide. Ann Rheum Dis 2013;72:129-35
63. List T, Neri D. Immunocytokines: A review of molecules in clinical development for cancer therapy. Clin Pharmacol 2013;5:29-45
64. Adams G, Vessillier S, Dreja H, et al. Targeting cytokines to inflammation sites. Nat Biotechnol 2003;21:1314-20
65. Vessillier S, Adams G, Chernajovsky Y. Latent cytokines: Development of novel cleavage sites and kinetic analysis of their differential sensitivity to MMP-1 and MMP-3. Protein Eng Des Sel 2004;17:829-35
66. Triantaphyllopoulos KA, Williams RO, Tailor H, et al. Amelioration of collageninduced arthritis and suppression of interferon-gamma, interleukin-12, and tumor necrosis factor alpha production by interferon-beta gene therapy. Arthritis Rheum 1999;42:90-9
67. Pepinsky RB, LePage DJ, Gill A, et al. Improved pharmacokinetic properties of a polyethylene glycol-modified form of interferon-beta-1a with preserved in vitro bioactivity. J Pharmacol Exp Ther 2001;297:1059-66
68. Mullen LM, Adams G, Chernajovsky Y. Increased disulphide dimer formation of latent associated peptide fusions of TGFbeta by addition of L-cystine. J Biotechnol 2012;161:269-77
69. Wakefield LM, Winokur TS, Hollands RS, et al. Recombinant latent transforming growth factor beta 1 has a longer plasma half-life in rats than active transforming growth factor beta 1, and a different tissue distribution. J Clin Invest 1990;86:1976-84
70. Brunner AM, Marquardt H, Malacko AR, et al. Site-directed mutagenesis of cysteine residues in the pro region of the transforming growth factor beta 1 precursor. Expression and characterization of mutant proteins. J Biol Chem 1989;264:13660-4
71. Mullen L, Adams G, Foster J, et al. A comparative study of matrix metalloproteinase and aggrecanase mediated release of latent cytokines at arthritic joints. Ann Rheum Dis 2013;In Press
72. Little CB, Flannery CR, Hughes CE, et al. Aggrecanase versus matrix metalloproteinases in the catabolism of the interglobular domain of aggrecan in vitro Latency can be conferred to a variety of cytokines. Biochem J 1999;15:61-8
73. Sandy JD, Verscharen C. Analysis of aggrecan in human knee cartilage and synovial fluid indicates that aggrecanase (ADAMTS) activity is responsible for the catabolic turnover and loss of whole aggrecan whereas other protease activity is required for C-Terminal processing in vivo. Biochem J 2001;358:615-26
74. Lohmander LS, Neame PJ, Sandy JD. The structure of aggrecan fragments in human synovial fluid. Evidence that aggrecanase mediates cartilage degradation in inflammatory joint disease, joint injury, and osteoarthritis. Arthritis Rheum 1993;36:1214-22
75. Fosang AJ, Last K, Maciewicz RA. Aggrecan is degraded by matrix metalloproteinases in human arthritis. Evidence that matrix metalloproteinase and aggrecanase activities can be independent. J Clin Invest 1996;98:2292-9
76. Lark MW, Bayne EK, Flanagan J, et al. Aggrecan degradation in human cartilage. Evidence for both matrix metalloproteinase and aggrecanase activity in normal, osteoarthritic, and rheumatoid joints. J Clin Invest 1997;100:93-106
77. Haddock G, Cross AK, Plumb J, et al. Expression of ADAMTS-1, -4, -5 and TIMP-3 in normal and multiple sclerosis CNS white matter. Mult Scler 2006;12:386-96
78. Vessillier S, Adams G, Montero-Melendez T, et al. Molecular engineering of short half-life small peptides (VIP, alphaMSH and gamma(3) MSH) fused to latency-Associated peptide results in improved anti-inflammatory therapeutics. Ann Rheum Dis 2012;71:143-9
79. Mullen LM, Rigby A, Sclanders M, et al. Latency can be conferred to a variety of cytokines by fusion with latency associated peptide from TGF-b. Expert Opin Drug Deliv 2013; In Press
80. Mullen L, Adams G, Fatah R, et al. Development of latent cytokine fusion proteins. In: Schmidt S, editor. Fusion protein technologies for biopharmaceuticals: Applications and challenges. John Wiley & Sons, Inc; of 111 River Street, Hoboken, NJ 07030: 2013
81. Tayal V, Kalra BS. Cytokines and anticytokines as therapeutics-An update. Eur J Pharmacol 2008;579:1-12
82. Shepherd J, Brodin H, Cave C, et al. Pegylated interferon alpha-2a and -2b in combination with ribavirin in the treatment of chronic hepatitis C: A systematic review and economic evaluation. Health Technol Assess 2004;8:1-125
83. Nissim A, Gofur Y, Vessillier S, et al. Methods for targeting biologicals to specific disease sites. Trends Mol Med 2004;10:269-74
84. Ebbinghaus C, Ronca R, Kaspar M, et al. Engineered vascular-Targeting antibody-interferon-gamma fusion protein for cancer therapy. Int J Cancer 2005;116:304-13
85. Hancox R, Allen M, Holliday D, et al. Tumour-Associated tenascin-C isoforms promote breast cancer cell invasion and growth by matrix metalloproteinasedependent and independent mechanisms. Breast Cancer Res 2009;11:R24
86. Rudman SM, Jameson MB, McKeage MJ, et al. A phase 1 study of AS1409, a novel antibody-cytokine fusion protein, in patients with malignant melanoma or renal cell carcinoma. Clin Cancer Res 2011;17:1998-2005
87. Schwager K, Bootz F, Imesch P, et al. The antibody-mediated targeted delivery of interleukin-10 inhibits endometriosis in a syngeneic mouse model. Hum Reprod 2011;26:2344-52